Verneri Virtanen

This study identifies SUMOylation as a therapeutic target in high-risk neuroblastoma, showing that SUMO pathway inhibitors like TAK-981 reduce tumor growth and are effective in combination with other therapies.

This study shows that BRCA1 supports prostate cancer cell survival during castration resistance by modulating mTOR signaling and NRF2-mediated antioxidant processes.

The paper examines the effects of caldesmon mutations in zebrafish embryos, finding mild developmental impacts and normal gross development, suggesting caldesmon may be a viable cancer therapy target.